|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
121,380,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. Co. is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. Co.'s Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, Co. is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
2,187 |
2,187 |
5,168 |
98,220 |
Total Buy Value |
$38,963 |
$38,963 |
$136,461 |
$2,585,297 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
2 |
4 |
Total Shares Sold |
100 |
6,000 |
10,991 |
31,616 |
Total Sell Value |
$1,905 |
$157,493 |
$334,111 |
$1,291,105 |
Total People Sold |
1 |
2 |
2 |
3 |
Total Sell Transactions |
1 |
3 |
6 |
11 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Meresman Stanley J |
Director |
|
2021-07-12 |
4 |
AS |
$124.27 |
$613,148 |
D/D |
(4,934) |
4,059 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-07-12 |
4 |
OE |
$5.94 |
$29,308 |
D/D |
4,934 |
8,993 |
|
- |
|
Clark Ian T |
Director |
|
2021-06-29 |
4 |
AS |
$130.00 |
$1,372,670 |
D/D |
(10,559) |
0 |
|
- |
|
Clark Ian T |
Director |
|
2021-06-29 |
4 |
OE |
$4.18 |
$377,613 |
D/D |
5,916 |
10,559 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-06-10 |
4 |
AS |
$113.60 |
$560,502 |
D/D |
(4,934) |
4,059 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-06-10 |
4 |
OE |
$5.94 |
$29,308 |
D/D |
4,934 |
8,993 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-05-10 |
4 |
AS |
$133.01 |
$656,271 |
D/D |
(4,934) |
4,059 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-05-10 |
4 |
OE |
$5.94 |
$29,308 |
D/D |
4,934 |
8,993 |
|
- |
|
Kaul Samir |
Director |
|
2021-05-05 |
4 |
AS |
$140.04 |
$714,242 |
I/I |
(5,000) |
14,943 |
|
- |
|
Clark Ian T |
Director |
|
2021-04-26 |
4 |
AS |
$159.92 |
$86,037 |
D/D |
(538) |
4,643 |
|
- |
|
Clark Ian T |
Director |
|
2021-04-26 |
4 |
OE |
$4.18 |
$2,249 |
D/D |
538 |
5,181 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-26 |
4 |
AS |
$160.01 |
$120,167 |
D/D |
(751) |
1,827,763 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-23 |
4 |
AS |
$160.12 |
$1,182,993 |
D/D |
(7,388) |
1,828,514 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-21 |
4 |
AS |
$148.35 |
$8,552,690 |
D/D |
(56,358) |
1,835,902 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-20 |
4 |
AS |
$148.10 |
$2,413,000 |
D/D |
(16,007) |
1,892,260 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-19 |
4 |
AS |
$151.17 |
$7,790,914 |
D/D |
(50,932) |
1,908,267 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-16 |
4 |
AS |
$157.09 |
$8,094,721 |
D/D |
(51,123) |
1,959,199 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-15 |
4 |
AS |
$156.67 |
$24,957,096 |
D/D |
(157,107) |
2,010,322 |
|
- |
|
Saia John G. |
See Remarks |
|
2021-04-15 |
4 |
D |
$159.20 |
$171,458 |
D/D |
(1,077) |
14,826 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-14 |
4 |
AS |
$154.49 |
$9,545,874 |
D/D |
(60,982) |
2,167,429 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-13 |
4 |
AS |
$153.78 |
$16,581,445 |
D/D |
(105,806) |
2,228,411 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-12 |
4 |
AS |
$151.80 |
$11,263,846 |
D/D |
(72,861) |
2,334,217 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-04-12 |
4 |
AS |
$151.91 |
$758,533 |
D/D |
(4,934) |
4,059 |
|
- |
|
Meresman Stanley J |
Director |
|
2021-04-12 |
4 |
OE |
$5.94 |
$29,308 |
D/D |
4,934 |
8,993 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2021-04-09 |
4 |
AS |
$155.89 |
$9,567,678 |
D/D |
(60,996) |
2,407,078 |
|
- |
|
671 Records found
|
|
Page 11 of 27 |
|
|